Compare Merck & Co., Inc. (MRK) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Weibo Corp — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Weibo Corp trades at $8 (market cap $1.95B). The key difference: Merck & Co., Inc. is far larger — about 157.6× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.63%). Which is the better fit depends on your goals.
| MRK | WB | |
|---|---|---|
Market Cap | $307.25B | $1.95B |
Sector | Health | Media |
52-Week High | $129.52 | $12.83 |
52-Week Low | $77.60 | $7.20 |
Enterprise Value | $350.66B | $1.22B |
Dividend Yield | 2.73% | 7.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Weibo (WB) trades at $8.00, up 3.23% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 21.15% net income margin and trades at discounted valuations including a P/E of 5.59 and P/B of 0.51. Recent earnings missed expectations for three consecutive quarters, but the company maintains robust cash flow generation and a solid balance sheet with $2.35 billion in cash.
The outlook is mixed: deep value metrics and analyst buy ratings (45%) support upside potential, but competitive pressures and recent earnings misses pose risks. The stock's 8% dividend yield provides income support while investors await improved execution and AI monetization opportunities to drive growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
